Focus:
Central Nervous System
-
20 September 2019 Research Reports
Global spinal muscular atrophy market set to reach US$6.6bn in 2028, says GlobalData
Spinal muscular atrophy (SMA) is a group of neurological disorders that cause a loss in muscle movement due to depleting motor neurons and progressive muscle wasting. The disease can be...
-
20 September 2019 Analysis
Vaccines for Alzheimer’s: exploiting similarities with Down syndrome
One approach to overcome continuing challenges facing drug research and development for Alzheimer’s is a vaccine. Swiss AC Immune has developed an Abeta-focused vaccine called ACI-24, which has been both...
-
19 September 2019 News
Novartis presents additional Zolgensma data in children with SMA
Novartis subsidiary AveXis has announced interim data for Zolgensma (onasemnogene abeparvovec-xioi) in children with spinal muscular atrophy (SMA) type 1, the most severe form of the neurodegenerative condition, for trials...
-
16 September 2019 News
Biogen and Eisai discontinue Alzheimer’s trials of BACE inhibitor
Biogen and Eisai have discontinued the clinical development programme of beta amyloid cleaving enzyme (BACE) inhibitor elenbecestat in early Alzheimer’s disease.
-
13 September 2019 News
Roche’s Ocrevus slows disease progression in two types of MS
Roche has announced Ocrevus (ocrelizumab) reduced the long-term risk of disability progression in patients with relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS) in two studies.
-
6 September 2019 whitepapers
Case Study: Bristol-Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company headquartered in New York City that specialises in discovering, developing and delivering innovative medicines for patients with serious diseases.
-
3 September 2019 News
Sandoz licences proposed multiple sclerosis biosimilar from Polpharma
Novartis unit Sandoz has signed an agreement with biopharmaceutical firm Polpharma Biologics for exclusive rights to commercialise a proposed biosimilar of Biogen’s multiple sclerosis drug natalizumab.
-
29 August 2019 News
FDA approves Kyowa Kirin’s Nourianz drug for Parkinson’s disease
The US Food and Drug Administration (FDA) has approved Japanese company Kyowa Kirin’s drug Nourianz (istradefylline) as an add-on to the existing drug levodopa/carbidopa to treat adults with Parkinson’s disease...
-
27 August 2019 Analysis
Treating SMA: moving beyond genetic approaches
As a result of dedicated efforts by the pharma industry, there are now two drugs approved for SMA: Spinraza and Zolgensma. Although these have been life-changing for patients with this...
-
27 August 2019 Comment
MELAS in the 16 major markets
Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS) is a rare progressive disorder that affects multiple systems in the body. Diagnosed prevalence of MELAS was found by GlobalData epidemiologists to...